Daily Cosmetic Research Analysis
Analyzed 40 papers and selected 3 impactful papers.
Summary
A phase II randomized intra-patient controlled trial shows that a bio-engineered autologous dermo-epidermal skin graft (denovoSkin) can improve scar quality versus split-thickness skin grafts. A randomized clinical study using SpiderMass ambient ionization mass spectrometry demonstrates noninvasive, real-time monitoring of sebum lipidomics in seborrheic dermatitis and supports maintenance therapy efficacy. A large preregistered cross-sectional analysis challenges a unifying silicone breast implant-related pathogenesis for Breast Implant Illness across cosmetic and reconstructive populations.
Research Themes
- Tissue-engineered autologous skin grafts to reduce scarring and donor-site morbidity
- Noninvasive lipidomic monitoring and inflammation biomarkers in seborrheic dermatitis
- Safety and symptomatology of silicone breast implants across cosmetic and reconstructive populations
Selected Articles
1. Safety and efficacy of bio-engineered, autologous dermo-epidermal skin grafts in reconstructive surgery: 1-year results of a prospective, randomized, intra-patient controlled, multicenter phase II clinical trial.
In a multicenter phase II randomized intra-patient controlled trial (n=23), denovoSkin, a bio-engineered autologous dermo-epidermal graft, achieved significantly better observer-rated scar quality at 3 months compared with paired split-thickness skin grafts. The platform addresses donor-site morbidity and cosmetic sequelae inherent to STSG while demonstrating safety over 1 year.
Impact: This RCT provides controlled clinical evidence that a tissue-engineered autologous skin substitute can improve scar outcomes versus current standard grafting. It advances reconstructive options by reducing donor-site morbidity and enhancing cosmetic results.
Clinical Implications: For full-thickness defects and burn scar revisions, denovoSkin may reduce donor-site morbidity and improve scar quality compared with STSG. Surgeons can consider intra-patient comparative application to optimize functional and cosmetic outcomes.
Key Findings
- Randomized intra-patient controlled design with 23 patients receiving both denovoSkin and STSG on comparable wounds.
- Observer-rated POSAS total score at 3 months favored denovoSkin (23.4) over STSG (27.9), indicating better scar quality.
- Feasibility and safety demonstrated over 1 year in a multicenter setting with a high proportion of post-burn scars (70%).
Methodological Strengths
- Prospective randomized intra-patient controlled multicenter design minimizes interpatient variability.
- Standardized scar assessment using observer-rated POSAS enhances outcome objectivity.
Limitations
- Phase II sample size (n=23) limits power and generalizability.
- Primary reported endpoint at 3 months; longer-term comparative scar metrics not fully detailed in abstract.
Future Directions: Larger phase III RCTs with longer follow-up and patient-reported outcomes should validate efficacy, cost-effectiveness, and indications (e.g., burns vs. traumatic defects).
Extensive full-thickness defects remain challenging to reconstruct, as various techniques used, such as split-thickness skin grafts, often result in donor site morbidity and functional and cosmetic scar sequelae. This study evaluated the safety and efficacy of denovoSkin™-a bio-engineered autologous dermo-epidermal skin graft consisting of patient-derived epidermal and dermal cells cultured within an extracellular matrix-compared to autologous split thickness skin grafts (STSG). Twenty-three patients (mean age 37.4 years; 65% male; 70% post-burn scars), received both denovoSkin™ and STSG on comparable wound areas. At 3 months, scar quality was significantly better for denovoSkin™ than for STSG (POSAS observer total score 23.4 vs 27.9;
2. Lipidomic Insights into Seborrheic Dermatitis: Clinical Evaluation of Sebum Changes Using SpiderMass.
In a randomized clinical study of 42 patients with scalp SD, SpiderMass enabled rapid, noninvasive lipidomic monitoring, showing increased glycerolipids and saturated fatty acids and decreased histamine, oxylipins, and arachidonic acid after 2 weeks of anti-SD shampoo. Improvements persisted only with once-weekly maintenance, and SpiderMass results correlated with LC-MS and reduced Malassezia levels.
Impact: This study introduces a clinically applicable ambient ionization MS platform to track inflammatory lipid signatures in SD, aligning with conventional LC-MS yet offering bedside feasibility. It links biochemical normalization to maintenance therapy adherence.
Clinical Implications: SpiderMass can serve as a noninvasive tool to monitor treatment response and optimize maintenance schedules in SD. Findings support continuing once-weekly anti-SD shampoo to sustain lipid balance and dampen inflammatory mediators.
Key Findings
- In 42 SD patients, 2 weeks of anti-SD shampoo increased glycerolipids and saturated fatty acids while reducing histamine, oxylipins, and arachidonic acid.
- Lipid normalization and reduced inflammatory markers persisted only in the maintenance group continuing once-weekly anti-SD shampoo.
- SpiderMass noninvasive profiling correlated with conventional LC-MS and with reductions in Malassezia levels.
Methodological Strengths
- Randomized controlled clinical design with defined intensive and maintenance phases.
- Cross-validation of SpiderMass readouts against LC-MS increases measurement validity.
Limitations
- Retrospective trial registration and modest sample size (n=42) limit external validity.
- Blinding details and clinical severity outcomes beyond biochemical markers are not fully specified.
Future Directions: Prospective preregistered RCTs assessing clinical severity scores, relapse rates, and patient-reported outcomes should confirm utility and define monitoring thresholds for SpiderMass-guided care.
INTRODUCTION: Seborrheic dermatitis (SD) is a skin disorder in which chronic inflammation of the scalp is linked to excessive sebum production and overgrowth of Malassezia fungi. These fungi break down sebum lipids, releasing pro-inflammatory unsaturated fatty acids. Lipidomic and metabolomic sebum analysis is thus essential to better understand SD. SpiderMass, an innovative ambient ionization mass spectrometry (AIMS) technology, allows for fast, direct, and non-invasive biochemical profiling of sebum. This study aimed to assess the potential of SpiderMass for evaluating the skin metabolome and lipidome in scalp SD and study the impact of an anti-SD shampoo (Kelual DS®) on the relative levels of SD-associated scalp metabolites and lipids. METHODS: Scalp sebum samples were obtained from 42 subjects with scalp SD enrolled in a randomized controlled clinical trial to assess the efficacy of the anti-SD shampoo. All participants used the anti-SD shampoo three times weekly for 2 weeks (intensive phase), followed by an 8-week maintenance phase in which subjects either continued to apply the anti-SD shampoo once weekly (KDS group) or switched to a neutral shampoo (control group). Sebum was collected during each study visit and analysed with SpiderMass. Additional biochemical analyses were also performed. RESULTS: After 2 weeks, SpiderMass analysis revealed a significant increase in the levels of glycerolipids and saturated fatty acids, alongside a reduction in the levels of inflammation markers such as histamine, oxylipins, and arachidonic acid. The change in lipid profile correlated with reduced Malassezia levels. During the maintenance phase, the more balanced lipid profile and lower inflammation marker levels were maintained only in the KDS group. SpiderMass findings were consistent with conventional liquid chromatography coupled to mass spectrometry (LC-MS) data. CONCLUSION: The anti-SD shampoo helped restore and maintain scalp lipid balance and reduce inflammation marker levels and may therefore contribute to improving skin barrier function in scalp SD. SpiderMass enabled real-time monitoring of changes in glycerolipids and inflammation markers, providing results consistent with those obtained using conventional LC-MS approaches. This reliable, powerful, non-invasive tool could be used as a rapid method for biochemical skin analysis in clinical studies, offering new insights into SD mechanisms and treatment responses. GOV IDENTIFIER: NCT06578962 (retrospectively registered on 28 August 2024).
3. A comparison of Breast Implant Illness-related symptoms between breast cancer survivors and breast augmentation recipients.
In a preregistered cross-sectional study (n=3,462), breast augmentation recipients reported more BII-related symptoms than breast cancer survivors with implant-based reconstruction, while survivors with implants did not report more symptoms than survivors without implants. Findings challenge a generic SBI-mediated pathogenesis across populations.
Impact: By contrasting cosmetic augmentation with oncologic reconstruction, this study provides nuanced evidence against a unitary implant-driven disease mechanism, informing risk counseling and policy.
Clinical Implications: Counseling should emphasize that BII-like symptoms are more frequently reported after cosmetic augmentation than after implant-based reconstruction and are not elevated versus non-implant cancer survivors. Shared decision-making should incorporate these differential risks.
Key Findings
- Cross-sectional Dutch cohort included 578 augmentation recipients and 2,884 breast cancer survivors (1,039 with implant-based reconstruction).
- Augmentation recipients had higher odds of myalgia (OR 2.10) and food intolerance (OR 1.77) than survivors with implants.
- Survivors with implants did not report more BII-related symptoms than survivors without implants; sensitivity analysis excluding systemic therapy reinforced findings.
Methodological Strengths
- Large sample with preregistration and multivariable logistic regression.
- Sensitivity analysis excluding systemic therapy recipients to address confounding.
Limitations
- Cross-sectional design precludes causal inference and is susceptible to reporting bias.
- Self-reported symptoms and potential residual confounding may influence estimates.
Future Directions: Prospective longitudinal cohorts with standardized symptom phenotyping and biomarker panels are needed to disentangle psychosocial, surgical, and device-related contributors.
BACKGROUND: 'Breast Implant Illness' (BII) refers to non-specific constitutional, rheumatic, mental and cognitive symptoms experienced by women with silicone breast implants (SBIs). This potential late effect of SBIs challenges the safety of SBI-use in oncologic breast reconstruction (BR). Previous studies on BII mainly focused on women with cosmetic SBIs. It remains unclear whether symptoms reported in this population differ from those reported by breast cancer (BC) survivors with SBI-based BR. METHODS: We conducted a cross-sectional survey in a Dutch cohort including 578 breast augmentation recipients and 2,884 BC survivors, of whom 1,039 had an SBI-based BR. Eighteen BII-related symptoms were assessed. Multivariable logistic regression was used to compare breast augmentation recipients with BC survivors with and without SBIs. RESULTS: Median follow-up time was 8.0 (IQR, 3.9) years. Overall, breast augmentation recipients had a higher risk of myalgia (Odds ratio (OR) 2.10, 95%CI [1.25-3.54]) and food intolerance (OR 1.77, 95%CI [1.01-3.09]) than BC survivors with SBIs, whereas the latter group did not report more BII-associated symptoms than BC survivors without SBIs. In a sensitivity analysis excluding BC patients treated with (neo)adjuvant systemic therapy, breast augmentation recipients reported more BII-related symptoms-headache, myalgia, hair loss, muscle weakness, sleep impairment, and morning stiffness (ORs 1.69-3.35; all p < 0.05) compared to BC survivors with SBIs. CONCLUSIONS: Breast augmentation recipients report more BII-related symptoms than BC survivors with or without SBIs. These findings do not support the hypothesis that BII is a distinct disease entity mediated by a generic SBI-related pathogenesis that exists across different populations.Trial registration: This study was preregistered at ClinicalTrials.gov on June 2 nd 2022 (NCT05400954).